| Protein | Protein Name | Molecular Type | Feature | Evidence | Reference |
|---|
| STAT5B | Signal transducer and activator of transcription 5B | Transcription Factor | Gene Amplification | STAT5B gene amplification occur during prostate cancer development. | Reference |
| MYC | V-myc avian myelocytomatosis viral oncogene homolog | Transcription Factor | Overexpression | c-MYC located at 8q24 is overexpressed during prostate cancer development. | Reference |
| MYC | V-myc avian myelocytomatosis viral oncogene homolog | Transcription Factor | Overexpression | Nuclear MYC protein overexpression is an early alteration in human prostatecarcinogenesis. | Reference |
| ESR1 | Estrogen receptor 1 | Transcription Factor | Genetic polymorphism | ESR1 (TA)(n) polymorphism is associated with prostate cancer risks. | Reference |
| ESR1 | Estrogen receptor 1 | Transcription Factor | Genetic polymorphism | Genetic polymorphism in ESR1 is associated with prostate cancer risks in both indian and american population. | Reference |
| TP53 | Tumor protein p53 | Transcription Factor | Mutation | TP53 mutation in exon7 and exon8 play an important role in prostate cancer development. | Reference |
| TP53 | Tumor protein p53 | Transcription Factor | Genome Instability | identification of LOH in these patients suggests that the TP53 tumor suppressor gene may play a more active role in prostate cancer | Reference |
| SMAD4 | SMAD family member 4 | Transcription Factor | Methylation | Promoter methylation of SMAD4 is associated with reduced expression in prostate cancer. | Reference |
| LPXN | Leupaxin | Adaptor Protein | Overexpression | Leupaxin(LPXN) mRNA is overexpressed in human prostate cancer and expression intensities strongly correlates with gleason score. | Reference |
| STAT3 | Signal transducer and activator of transcription 3 (acute-phase response factor) | Transcription Factor | Overexpression | STAT3 gene is overexpressed in human prostate cancer. | Reference |
| RB1 | Retinoblastoma 1 | Transcription Regulatory Protein | Genome Instability | Loss of heterogygosity for RB1 gene is frequently observed in invasive prostate cancer and prostatic intraepithelial neoplasia (PIN). | Reference |
| RB1 | Retinoblastoma 1 | Transcription Regulatory Protein | Epigenetic Silencing | In castration resistant prostate cancer, RB1 gene is frequently deleted and methylated. | Reference |
| SMAD3 | SMAD family member 3 | Transcription Regulatory Protein | Overexpression | SMAD3 is overexpressed in human prostate cancer and its expression correlates with gleason score. | Reference |
| AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | GTPase | Mutation | Missense mutation of AGAP2 gene is present in prostate cancer and associated with aggressive clinical behavior. | Reference |
| KRAS | Kirsten rat sarcoma viral oncogene homolog | GTPase | Mutation | Mutation in KRAS gene causes oncogenic activation and plays a role in prostate cancer development and pathogenesis in Japanese men. | Reference |
| KRAS | Kirsten rat sarcoma viral oncogene homolog | GTPase | Mutation | Mutation in KRAS gene has been found in prostate adenocarcinoma. | Reference |
| PABPC1 | Poly(A) binding protein, cytoplasmic 1 | RNA Binding Protein | Overexpression | PABPC1 located at 8q22.3 is overexpressed in prostate cancer. | Reference |
| IMP3 | Insulin-like growth factor 2 mRNA binding protein 3 | Translation Regulatory Protein | Overexpression | Oncofetal protein insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in human prostate cancer and correlates with Gleasons score | Reference |
| IL12A | Interleukin 12A | Cytokine | Gene Amplification | IL12A gene located at 3q25-q26.2 is amplified in human prostate cancer. | Reference |
| SOCS3 | Suppressor of cytokine signaling 3 | Adaptor Protein | Overexpression | SOCS3 is overexpressed in castration resistant prostate tumour | Reference |
| DAB2 | Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) | Adaptor Protein | Loss of Expression | In many prostate cancer cell line, DAB2 suffers from loss of expression | Reference |
| BIN1 | Bridging integrator 1 | Adaptor Protein | Epigenetic Silencing | BIN1 gene promoter CpG island is frequently methylated and epigenetically inactivated in prostate cancer | Reference |
| BIN1 | Bridging integrator 1 | Adaptor Protein | Aberrant Splicing | BIN1 is most frequently inactivated by aberrant splicing in metastatic tumours. | Reference |
| YWHAZ | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta | Adaptor Protein | Gene Amplification | YWHAZ is amplified in castration resistant prostate cancer | Reference |
| DVL1 | Dishevelled segment polarity protein 1 | Adaptor Protein | Overexpression | DVL1 is overexpressed in prostate cancer and possibly related to prostate cancer progression by Wnt/beta catenine pathway | Reference |
| FHL2 | Four and a half LIM domains 2 | Adaptor Protein | Overexpression | FHL2 is overexpressed in prostate cancer | Reference |
| DAXX | Death-domain associated protein | Adaptor Protein | Genome Instability | Daxx may function as a APC/C inhibitor and enhancess chromosome instability during prostate cancer progression | Reference |
| DAXX | Death-domain associated protein | Adaptor Protein | Overexpression | DAXX is frequently overexpressed in prostate cancer | Reference |
| HRK | Harakiri, BCL2 interacting protein | Adaptor Protein | Genome Instability | HRK is inactivated by 12q13.1 loss of heterozygosity (LOH) | Reference |
| HRK | Harakiri, BCL2 interacting protein | Adaptor Protein | Methylation | HRK in prostate cancer is inactivated by promoter hypermethylation | Reference |
| SOCS1 | Suppressor of cytokine signaling 1 | Adaptor Protein | Methylation | SOCS1 gene is methylated in prostate cancer | Reference |
| BECN1 | Beclin 1, autophagy related | Adaptor Protein | Genome Instability | Beclin1 is most commonly deleted in prostate cancer | Reference |
| NOD1 | Nucleotide-binding oligomerization domain containing 1 | Adaptor Protein | Genetic polymorphism | NOD1 gene polymorphism may be associated with altered risks for prostate cancer | Reference |
| PARD3 | Par-3 family cell polarity regulator | Adaptor Protein | Mutation | In prostate cancer cell, PARD3 gene is inactivated through a biallelic mutation | Reference |
| BCL2L1 | BCL2-like 1 | Adaptor Protein | Overexpression | BCL2L1 is overexpressed and contributes to androgen resistance in prostate cancer | Reference |
| AXIN1 | Axin 1 | Adaptor Protein | Mutation | Potentially functionally relevant AXIN1 mutations has been found in advanced prostate cancer patients. | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Loss of Expression | Frequent loss of TGFBR2 expression | Reference |
| TGFBR2 | Transforming growth factor, beta receptor II | Receptor Serine/threonine Kinase | Loss of Expression | Frequent loss of TGFBR2 expression is assocoated with the development of human prostate cancer. | Reference |
| BMPR2 | Bone morphogenetic protein receptor, type II (serine/threonine kinase) | Receptor Serine/threonine Kinase | Loss of Expression | Loss of BMPR2 expression is responsible for prostate cancer pathogenesis, loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells | Reference |
| IGF1R | Insulin-like growth factor 1 receptor | Receptor Tyrosine Kinase | Overexpression | IGF1R is overexppressed in human prostate cancer. | Reference |
| EPHB2 | EPH receptor B2 | Receptor Tyrosine Kinase | Mutation | Frameshift, splice site, missense and nonsense mutations are found in the EPHB2 gene in clinical prostate cancer samples. | Reference |
| EGFR | Epidermal growth factor receptor | Receptor Tyrosine Kinase | Gene Amplification | EGFR gene is amplification frequently in advanced hormone refractory prostate cancer. | Reference |
| EGFR | Epidermal growth factor receptor | Receptor Tyrosine Kinase | Overexpression | EGFR is overexpressed in prostatetumour and in prostate cancer cell line DU145. | Reference |
| RET | Ret proto-oncogene | Receptor Tyrosine Kinase | Overexpression | RET is overexpressed in histopathologically advanced prostatic intraepithelial neoplasia (PIN). | Reference |
| PIK3R1 | Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | Adaptor Protein | Genetic polymorphism | PIK3R1 single neuceotide polymorphism associates with aggressive prostate cancer in Caucasian and African American men. | Reference |
| FGFR1 | Fibroblast growth factor receptor 1 | Receptor Tyrosine Kinase | Genome Instability | FGF-2/FGFR1/CEP57 signaling axis is involved in mitotic instability of prostate cancer. | Reference |
| FGFR1 | Fibroblast growth factor receptor 1 | Receptor Tyrosine Kinase | Overexpression | FGFR1 is overexpressed in advanced prostate cancer. | Reference |
| MET | Met proto-oncogene | Receptor Tyrosine Kinase | Overexpression | c-MET is overexpressed in human prostate cancer and is associated with dedifferentiation of prostate adenocarcinoma. | Reference |
| ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Receptor Tyrosine Kinase | Overexpression | HER-2/neu(ERBB2) is overexpressed in androgen independent prostate cancer and is linked with tumour stage and Gleason score. | Reference |
| EPHA2 | EPH receptor A2 | Receptor Tyrosine Kinase | Overexpression | EPHA2 is overexpressed in prostate cancer. | Reference |
| IL6ST | Interleukin 6 signal transducer | Cytokine Receptor | Genetic polymorphism | IS6ST gene polmorphism is significantly associated with prostate cancer risks in caucasian | Reference |
| IL6ST | Interleukin 6 signal transducer | Cytokine Receptor | Genetic polymorphism | Single nuceotide polymorphism of the IL6ST gene is significantly associated with prostate cancer risks in Caucasian and african american population. | Reference |
| CXCR4 | Chemokine (C-X-C motif) receptor 4 | G protein Coupled Receptor | Overexpression | CXCR4 overexpression is associated with prostate tumorigenesis | Reference |
| NGFR | Nerve growth factor receptor | Cell Surface Receptor | Loss of Expression | 3' UTR are involved in loss of p75(NTR) expression in prostate cancer. | Reference |
| AR | Androgen receptor | Nuclear Receptor | Mutation | Mutation in Androgen receptor causes relaxation of AR ligand specificity | Reference |
| AR | Androgen receptor | Nuclear Receptor | Gene Amplification | Androgen receptor (AR) gene as a target gene for the Xq12 amplification found in one-third of the hormone-refractory prostate cancer | Reference |
| AR | Androgen receptor | Nuclear Receptor | Aberrant Splicing | Androgen receptor splice variants AR3 is the most abundantly expressed variants that propels tumorigenesis under androgen deprivation condition | Reference |
| VAV3 | Vav 3 guanine nucleotide exchange factor | Guanine Nucleotide Exchange Factor | Overexpression | VAV3 is overexpressed in androgen-independent prostate cancer. | Reference |
| TIAM1 | T-cell lymphoma invasion and metastasis 1 | Guanine Nucleotide Exchange Factor | Overexpression | TIAM1 is overexpressed in prostate cancer and its expression is corelated with disase aggressiveness. | Reference |
| GOLM1 | Golgi membrane protein 1 | Transport/Cargo Protein | Overexpression | Golgi membrane protein 1 (GOLM1) is overexpressed in human prostate cancer tissue. | Reference |
| ST7 | Suppression of tumorigenicity 7 | Cell Cycle Control Protein | Epigenetic Silencing | its primary mechanism of inactivation is via epigenetic downregulation, haplo-insufficiency or post-translational modification of the ST7 protein | Reference |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | Cell Cycle Control Protein | Methylation | CDKN1A(p21) is inactivated in metastatic prostate cancer through promoter hypermethylation. | Reference |
| APC | Adenomatous polyposis coli | Adhesion Molecule | Methylation | Methylation of the promoter of APC gene is associated with advanced grade of human prostate cancer. | Reference |
| RAF1 | V-raf-1 murine leukemia viral oncogene homolog 1 | Serine/Threonine Kinase | Gene Amplification | Activation of the RAS/RAF/MEK/ERK pathway play an important role in prostate cancer development along with RAF gene copy number gain. | Reference |
| RAF1 | V-raf-1 murine leukemia viral oncogene homolog 1 | Serine/Threonine Kinase | Gene Amplification | Gene amplification of RAF1 occur much more frequently during progression from hormone-sensitive to hormone-resistant cancer. | Reference |
| PRKCE | Protein kinase C, epsilon | Serine/Threonine Kinase | Overexpression | PRKCE is overexpressed in human prostate cancer. | Reference |
| PLK1 | Polo-like kinase 1 | Serine/Threonine Kinase | Overexpression | Polo-like kinase 1 (PLK1) is overexpressed during prostate cancer development and asociated with higher tumour grade. | Reference |
| PTK2B | Protein tyrosine kinase 2 beta | Tyrosine Kinase | Loss of Expression | PTK2B located on chromosome 8p21.1 is frequently associated with allelic loses in prostate cancer. | Reference |
| FYN | FYN oncogene related to SRC, FGR, YES | Tyrosine Kinase | Genome Instability | FYN is downregulated in prostate cancer by both chromosomal deletion and promoter hypermethylation, and therefore is a novel prostate tumor suppressor gene candidate. | Reference |
| FYN | FYN oncogene related to SRC, FGR, YES | Tyrosine Kinase | Overexpression | FYN is overexpressed during prostate cancer progression. | Reference |
| ATP2A2 | ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 | Membrane transport protein | Overexpression | ATP2A2(SERCA2) is overexpressed in PC3 prostate cancer cell line. | Reference |
| EGFR | Epidermal growth factor receptor | Receptor Tyrosine Kinase | Mutation | Somatic mutation in tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR) gene has been detected in chinese prostate cancer patients. | Reference |
| ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Receptor Tyrosine Kinase | Gene Amplification | ERBB2 (HER2) gene amplification has been reported in human prostate cancer which is associated with cancer progression, poor prognosis or development of androgen independence. | Reference |
| MYC | V-myc avian myelocytomatosis viral oncogene homolog | Transcription Factor | Gene Amplification | c-MYC oncogene is amplified in human prostate cancer and plays a very important role in prostate cancer development and progression. | Reference |
| PIAS1 | Protein inhibitor of activated STAT, 1 | Cell Cycle Control Protein | Overexpression | PIAS1, a cytokine signaling modulator and cell cycle regulator which is overexpressed in local and metastatic prostate cancer cell and mediates docetaxel resistant prostate cancer cell survival. | Reference |
| MED12 | Mediator complex subunit 12 | Transcription Regulatory Protein | Mutation | Somatic mutation is present in exon 26 of MED12 (Mediator complex subunit 12) and plays an important role in prostate tumorigenesis. | Reference |
| SPOP | Speckle type POZ protein | Transcription Regulatory Protein | Mutation | SPOP gene mutation (one of the most common point mutation in prostate cancer which involves the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts) mediates prostate cancer development in part through genomic instability via modulation of DNA double strand break (DSB) repair. | Reference |
| FOXA1 | Forkhead box A1 | Transcription Factor | Mutation | Recurrent mutation in FOXA1 (a key metastatic inhibitor in human prostate cancer) plays a crucial in prostate cancer development through effecting cell motility. | Reference |
| BRCA2 | Breast cancer 2 | Transcription Regulatory Protein | Mutation | Mutation in BRACA2 (a high risk prostate cancer susceptibility gene) plays a role in prostate cancer development and presence of BRACA2 mutation significantly enhances prostate cancer associated risks. | Reference |
| BRCA1 | Breast cancer 1 | Transcription Regulatory Protein | Mutation | Mutation in BRACA1 occurs during prostate cancer development and presence of BRACA1 mutation significantly enhances high grade prostate cancer development associated risks. | Reference |
| HOXB13 | Homeobox B13 | Transcription Factor | Mutation | A nonconservative substitution mutation (G84E) is present in HOXB13 and is associated with prostate cancer risk. | Reference |
| POLK | Polymerase (DNA directed) kappa | DNA Binding Protein | Mutation | Somatic mutation (that mainly involves C-to-T transitions) is present in the catalytic core of DNA polymerase kappa which may be involved in human prostate cancer progression. | Reference |
| HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzyme Isomerase | Genetic polymorphism | Allelic variation in HSD3B1 (1245C) is significantly associated with castration resistant prostate cancer (CRPC) progression. | Reference |
| WWOX | WW domain containing oxidoreductase | Enzyme Oxidoreductase | Loss of Expression | WWOX, which functions as a key tumour suppressor in human prostate cancer, suffers from loss of heterozygosity (LOH) or loss of one allele in 53% of human prostate carcinoma. | Reference |
| CHEK2 | Checkpoint kinase 2 | Serine/Threonine Kinase | Mutation | Checkpoint kinase 2 (CHK2), a critical negative growth regulator which plays a significant role in prostate cancer cell growth is inactivated through a frame-shift mutation (1100delC) that abrogates its kinase activity. | Reference |
| XRCC1 | X-ray repair complementing defective repair in Chinese hamster cells 1 | DNA Repair protein | Genetic polymorphism | X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism is significantly associated with prostate cancer development. | Reference |
| OLFM4 | Olfactomedin 4 | Unclassified | Genome Instability | Olfactomedin 4 (OLFM4), a chromosome 13q tumour suppressor, has been reported for homozygous deletion in human prostate cancer and is associated with advanced prostate cancer development . | Reference |
| SND1 | Staphylococcal nuclease and tudor domain containing 1 | Transcription Regulatory Protein | Aberrant Splicing | SND1, a transcriptional co-activator, functions as a novel regulator of alternative splicing in human prostate cancer that particularly enhances prostate cancer cell growth and survival. | Reference |
| NBN | Nibrin | DNA Repair protein | Mutation | NBN, a prostate cancer susceptibility gene and a classical tumour suppressor, suffers from biallelic mutational inactivation in human prostate cancer. | Reference |
| KLF6 | Kruppel-like factor 6 | Transcription Factor | Mutation | Kruppel-like factor 6, a transcription factor and a tumour suppressor is frequently inactivated in human prostate cancer through somatic mutation. | Reference |
| KLF6 | Kruppel-like factor 6 | Transcription Factor | Aberrant Splicing | Kruppel-like factor 6, a transcription factor and a tumour suppressor is frequently inactivated in human prostate cancer through alternative splicing. | Reference |
| PTEN | Phosphatase and tensin homolog | Lipid Phosphatase | Genome Instability | Inactivation of PTEN tumour suppressor through either homozygous deletion or deletion of one allele and mutation of the other, most crucially drives human prostate cancer and its progression to castration resistance. | Reference |
| AQP5 | Aquaporin 5 | Water Channel | Overexpression | Aquaporin 5 (AQP5) is overexpressed in human prostate cancer and plays a role in prostate cancer cell growth and metastasis. | Reference |
| AURKA | Aurora kinase A | Serine/Threonine Kinase | Gene Amplification | Aurora kinase A (AURKA) gene amplification with a high frequency has been reported in human prostate cancer and is associated with presence of ductal features and higher overall Gleason grade. | Reference |
| MED15 | Mediator complex subunit 15 | Transcription Regulatory Protein | Overexpression | MED15 is overexpressed in metastatic castration resistant prostate cancer and enhances both androgen dependent and independent prostate cancer cell proliferation. | Reference |
| STAT5A | Signal transducer and activator of transcription 5A | Transcription Factor | Gene Amplification | STAT5A gene is amplified in human prostate cancer and provides the enhancement of prostate cancer cell growth. | Reference |
| VCL | Vinculin | Cytoskeletal associated protein | Gene Amplification | Vinculin (VCL), a cytoskeletal associated protein is highly amplified in human castration resistant prostate cancer and particularly promotes prostate cancer cell proliferation. | Reference |
| BAG1 | BCL2 associated athanogene 1 | Transcription Factor | Gene Amplification | BAG1 gene amplification plays an important role in prostate cancer development and its castration resistant disease progression. | Reference |
| KCNMA1 | Potassium channel, calcium activated large conductance subfamily M alpha, member 1 | Ion channel | Gene Amplification | Large conductance calcium-activated potassium channel alpha subunit (KCNMA1), which is located at the chromosomal region 10q22 is amplified in human prostate cancer and drives prostate tumour cell proliferation. | Reference |
| MCM7 | Minichromosome maintenance complex component 7 | Enzyme DNA helicase | Gene Amplification | MCM7, a component of the DNA replication licensing complex, is amplified in human prostate cancer and promotes prostate cancer progression through enhancement of cell proliferation. | Reference |
| PSAP | Prosaposin | Integral Membrane Protein | Gene Amplification | Prosaposin (PSAP), a secreted protein is amplified in human prostate cancer and promotes prostate cancer progression. | Reference |
| PIM1 | Pim-1 proto-oncogene, serine/threonine kinase | Serine/Threonine Kinase | Genome Instability | PIM1 kinase, a serine/threonine kinase that is overexpressed in human prostate cancer, promotes genomic instability in prostate cancer and there by mediates multiple roles in prostate tumorigenesis. | Reference |
| KLK2 | kallikrein related peptidase 2 | Serine Protease | Genome Instability | SPOP gene mutation drives human prostate cancer development through genomic instability via modulation of DNA double strand break (DSB) repair. | Reference |
| HOOK3 | Hook microtubule-tethering protein 3 | Adaptor protein | Genome Instability | Hook microtubule-tethering protein 3 (HOOK3), an adaptor plays a very important role in maintaining the genomic integreity in human prostate cancer and its expression is strongly associated with classical parameters such as enhancement of chromosomal deletions and cellular proliferation. | Reference |
| LIMK1 | LIM domain kinase 1 | Serine/Threonine Kinase | Genome Instability | LIM kinase 1 (LIMK1), a LIM domain containing serine/threonine kinase, promotes genomic instability in prostate cancer cell. | Reference |
| PIM1 | Pim-1 proto-oncogene, serine/threonine kinase | Serine/Threonine Kinase | Genome Instability | PIM1, which is overexpressed in advanced human prostate cancer, mediates genomic instability in prostate cancer through promoting polyploidy and multinucleation. | Reference |